Best Life Sciences Companies in Buffalo, United States
The 46 best Life Sciences companies in Buffalo, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Athenex.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Buffalo
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Athenex Developer of therapies for the treatment of multiple cancers | $147M | 80 mo ago | 318 | — | Deadpooled | 120 patents Design of biaryl small‑molecule kinase inhibitors and oral chemo‑immunotherapy formulations | — |
| 2 | Cleveland BioLabs Online gaming center offering slot games and deposit options | $124M | 74 mo ago | 46 | — | Public | 139 patents Toll‑like receptor agonist and flagellin‑based immunotherapeutics for cancer, vaccines, and radiation injury | — |
| 3 | Circuit Clinical Research site network platform focuses on patient identification, enrollment, recruitment & retention | $48M | 29 mo ago | 96 | Ray Stapell Co-Founder & Special Legal Advisor | Series C | — | — |
| 4 | Tactiva Therapeutics Innovative cancer immunotherapy company developing next-generation adoptive T cell therapies | $35M | 92 mo ago | 4 | — | Series A | — | — |
| 5 | Therapyxinc Innovating microparticulate immune therapeutics for cancer, infectious disease, and inflammatory disorders 14Innovation top 43%Funding top 44%Product bottom 44%Global bottom 32% All 6 signals ▾Innovationtop 43% Fundingtop 44% Productbottom 44% Globalbottom 32% Techbottom 25% Marketbottom 19% Innovation: 2 product lines Funding: Raised $17.7M across 5 rounds · 5 rounds over 18 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 14/100 | $18M | 16 mo ago | 11 | — | Funding Raised | — | — |
| 6 | OncoTartis Developing tissue-specific anti-cancer drugs for hematological malignancies, breast, prostate, ovarian… | $14M | 104 mo ago | 3 | Alexander Polinsky CEO | Series B | 28 patents Patents concentrated in chemistry & materials | — |
| 7 | SmartPill Developer of monitoring device for detecting gastrointestinal disorders | $10M | 192 mo ago | 25 | David L. Barthel President/CEO | Acqui-Hired | 24 patents Ingestible diagnostic capsules for gastrointestinal monitoring and constipation assessment | — |
| 8 | OmniSeq Labcorp Oncology: Advancing cancer care through diagnostics, research, and precision medicine | $9M | 86 mo ago | 57 | — | Series B | 25 patents AI-driven cancer genomics and biomarker analytics for personalized oncology therapies | — |
| 9 | Cytocybernetics Electrophysiology solutions: dynamic clamp, voltage-sensitive dyes, model builder, and analysis | $5M | 49 mo ago | 19 | Glenna Bett Co-Founder & CEO | Funding Raised | — | — |
| 10 | Empire Genomics Provider of molecular diagnostics tests for disease detection | $5M | 123 mo ago | 14 14 → 23 (+64%) | — | Acquired | — | 2 launchs · 1 partnership |
| 11 | Photolitec Photosensitizing compounds for tumor imaging and image-guided photodynamic cancer therapy. | $5M | 71 mo ago | 11 | Ravindra Pandey Founder & CSO | Deadpooled | 13 patents Patents concentrated in health & consumer products | — |
| 12 | Vicora Developer of a thrombectomy system utilizing integrated distal tip vibration | $3M | 18 mo ago | — | Shawn Patterson CEO | Series A | 10 patents Electroactive polymer actuators for minimally invasive medical devices, e.g., thrombectomy tools. | — |
| 13 | Canget Bio Tekpharma Developing cancer-targeting agents with low toxicity and high efficacy | $3M | 35 mo ago | 8 | — | Seed | — | — |
| 14 | For-Robin Therapeutics Developing cancer therapeutics, driven by personal mission, for clinical trials | $3M | 89 mo ago | 2 | Kate Rittenhouse Founder & President | Funding Raised | — | — |
| 15 | POP BIO Developer of nanomedicines to treat oncology and infectious diseases | $2M | 15 mo ago | 5 | Jonathan Smyth Co-Founder | Funding Raised | — | — |
| 16 | MimiVax Disrupting cancer with innovative immunotherapies aimed at increasing patient survival rates | $2M | 13 mo ago | 3 | — | Series A | 2 patents Therapeutic antibodies targeting survivin for cancer treatment | — |
| 17 | LegWorks Innovative prosthetic knees empowering amputees with mobility, stability, and confidence | $1M | 94 mo ago | 3 | Brandon Burke Co-Founder & Director | Seed | 2 patents Prosthetic knee joint swing-phase control using variable friction mechanisms | — |
| 18 | HemoGenyx Developer of cell and gene therapies to treat blood diseases and viral infections | $1M | 6 mo ago | 14 | — | Public | 6 patents Bispecific antibody-mediated depletion of hematopoietic stem and progenitor cells | — |
| 19 | Efferent Labs Revolutionizing preclinical research with live, cellular data acquisition platform | $960K | 103 mo ago | 5 | Bill Rader Founder & CEO | Seed | 51 patents Integrating clinical data and enabling intra-body communication for wearable/implantable health sensors | — |
| 20 | AndroBioSys Novel treatments for prostate disease | $700K | 186 mo ago | — | Michael Zwick ex-CEO | Deadpooled | — | — |
| 21 | Infiuss Health Cloud-based patient recruitment platform for clinical trial studies | $625K | 46 mo ago | 7 | — | Seed | — | — |
| 22 | Kodikaz Developer of gene transfer technology platform for treating multiple diseases | $256K | 60 mo ago | 8 | Anthony Johnson Co-Founder & CEO | Funding Raised | — | — |
Top 12 Life Sciences companies in Buffalo
#1
Funding Raised · Buffalo, New York · founded 2001 · 11 employees$17.7Mraised▾
Innovating microparticulate immune therapeutics for cancer, infectious disease, and inflammatory disorders. This biotechnology company is focused on discovering and developing advanced therapies using its unique technology for sustained-release microparticulate protein therapeutics. These biologics are formulated for parenteral, oral, and mucosal delivery. The company aggressively protects its innovations through patent filings. It is developing both therapeutic and prophylactic vaccines. The company is dedicated to changing the future of pharmaceuticals by addressing critical unmet needs in cancer, infectious diseases, and inflammatory disorders. This involves research and development of first-in-class immune therapies.
- Apr 2025Grant (prize money)$5.2M
- Jun 2013Grant (prize money)$6M
- Mar 2011Grant (prize money)—
- Mar 2011Grant (prize money)$6M
#2
Public · Buffalo, New York · founded 2014 · 14 employees$1Mraised▾
Developer of cell and gene therapies to treat blood diseases and viral infections. It offers apipeline of drug candidates which include HG‑CT‑1 CAR‑T therapy for relapsed or refractory acute myeloid leukemia, CDX Bi‑specific antibody to eliminate malignancy in patients with FLT3+ R/R AML and potentially condition bone marrow transplant, and Chimeric Bait Receptor Platform for antiviral and cancer immune cell reprogramming.
- Feb 2026Post IPO$3.4M
- Mar 2025Post IPO$915.1K
- Jan 2025Post IPO$425.6K
- Mar 2024Post IPO$4.5M
#3
Series A · Buffalo, New York · founded 2012 · 3 employees$1.6Mraised▾
Disrupting cancer with innovative immunotherapies aimed at increasing patient survival rates. It is a biopharmaceutical company focused on developing novel immunotherapies for cancer treatment. Their lead product, SurVaxM, is a peptide-based immunotherapeutic vaccine targeting survivin, a protein overexpressed in many cancer cells. This approach stimulates the immune system to recognize and attack cancer cells while sparing healthy tissue. They are conducting clinical trials to evaluate the safety and efficacy of SurVaxM for glioblastoma, multiple myeloma, neuroendocrine tumors and pediatric brain tumors. The company leverages its proprietary survivin-targeting technology to explore new ways of stimulating the immune system to fight cancer cells. They are committed to improving outcomes and quality of life for those suffering from devastating diseases. The company collaborates with leading clinicians and scientists to deliver on the promise of SurVaxM and other products to improve the lives of patients battling cancer.
- Jul 2025Series A$500K
- Jan 2025Grant (prize money)$409.6K
- Jan 2024Series A—
- Oct 2023Conventional Debt$5.8M
#4
Funding Raised · Buffalo, New York · founded 2015 · 5 employees$2.5Mraised▾
Developer of nanomedicines to treat oncology and infectious diseases. The company has two patented porphyrin-phospholipid (PoP) liposome technologies which include a spontaneous nanoliposome antigen particleization (SNAP) platform for immunogenic vaccines and chemophototherapy (CPT) using PoP liposomes.
- May 2025Grant (prize money)$1.9M
- Feb 2025Grant (prize money)$600K
#5
Series C · Buffalo, New York · founded 2014 · 96 employees$47.7Mraised▾
Research site network platform focuses on patient identification, enrollment, recruitment & retention
- Mar 2024Series C$3M
- Jan 2022Series C$29M
- Mar 2021Series B$7.5M
- Dec 2020Series A$2.5M
#6
Series A · Buffalo, New York · founded 2021$3.4Mraised▾
Developer of a thrombectomy system utilizing integrated distal tip vibration. The system is designed for clot removal without capital equipment. It focuses on trackability to improve clot removal efficiency. The device is currently in the research and development phase and not available for sale.
- Jan 2025Series A$3.4M
#7
Deadpooled · Buffalo, New York · founded 2003 · 318 employees$146.5Mraised▾
Developer of therapies for the treatment of multiple cancers. It offers autologous and allogeneic NKT cell therapies which include KUR-501 for neuroblastoma, KUR-502 for leukemia, KUR-503 for HCC, Oral paclitaxel + encequidar for breast cancer and solid tumors
- Dec 2019Post IPO$60.4M
- May 2019Post IPO$100M
- Jul 2018Post IPO$100M
- May 2017Conventional Debt$20M
#8
Public · Buffalo, New York · founded 2003 · 46 employees$123.7Mraised▾
Online gaming center offering slot games and deposit options, providing a platform for online slot games. It focuses on delivering a user-friendly experience with various deposit methods. The platform emphasizes accessibility and customer service, aiming to create an engaging environment for players. It offers a range of slot games and strives to provide a seamless gaming experience. The business model includes online entertainment, gaming services, and customer support. It is a B2C company in the entertainment industry. The website includes features like login, account creation, and a cart system. It also offers bonus programs and contact options for customer support.
- Jun 2020Post IPO$1.6M
- Dec 2015Post IPO$1.1M
- Sep 2015Grant (prize money)$6.6M
- Sep 2015Grant (prize money)$6.6M
#9
Seed · Buffalo, New York · founded 2012 · 8 employees$3Mraised▾
Developing cancer-targeting agents with low toxicity and high efficacy. This biotech and biopharma company focuses on creating innovative anticancer solutions to improve patient survival. They address challenges like drug resistance and metastasis by providing highly effective, low-toxic, and cancer-targeting agents. Their mission is to dramatically improve cancer patient outcomes through eliminating drug resistance and tumor relapse. They aim to establish best practices in innovation and drug development, improving the quality of life for cancer patients. They collaborate with research institutions to develop new products and offer compounds for research use, contributing to advancements in cancer treatment.
- Sep 2023Grant (prize money)$400K
- Jul 2019Seed$25K
- Aug 2018Grant (prize money)$224.9K
- Aug 2014Grant (prize money)$2.3M
#10
Series A · Buffalo, New York · founded 2017 · 4 employees$35Mraised▾
Innovative cancer immunotherapy company developing next-generation adoptive T cell therapies. They are focused on engineering immune cells for potent cancer treatment, specifically targeting cancer in a specific, efficient, and durable manner. Their approach utilizes a unique class of CD4 T cells to enhance the anti-tumor function of CD8 T cells, directly targeting tumor cells. The platform harnesses the synergistic effects of CD8-TCRs and CD4-TCRs, and HSC derived T cells, to provide durable remission for cancer patients. This immuno-oncology company specializes in potent cancer immunotherapy using a dual T cell receptor approach, including genetic modification of patients’ mature T cells and reprograming patient derived hematopoietic stem cells (HSCs). This creates a continual, long-term source of cancer-fighting T cells, leading to sustained attack on cancer cells.
- Dec 2018Series A$35M
#11
Funding Raised · Buffalo, New York · founded 2013 · 19 employees$5.4Mraised▾
Electrophysiology solutions: dynamic clamp, voltage-sensitive dyes, model builder, and analysis. The company provides equipment and software to simplify electrophysiology research. They offer dynamic clamp systems, voltage-sensitive dyes, a model builder, and analysis tools for drug safety screening. Their products cater to researchers and scientists in the fields of electrophysiology, pharmacology, and drug discovery. The company's offerings include user-friendly, plug-and-play systems, enabling researchers to build and use models easily. They also provide custom services to meet specific research needs. Their solutions support ion channel research, drug development, and safety pharmacology.
- Jul 2022Grant (prize money)$256.6K
- Jul 2020Grant (prize money)$250K
- Jul 2019Grant (prize money)$269.9K
- Sep 2018Grant (prize money)$2.4M
#12
Series B · Buffalo, New York · founded 2010 · 3 employees$14.2Mraised▾
Developing tissue-specific anti-cancer drugs for hematological malignancies, breast, prostate, ovarian, melanoma. This biotechnology company focuses on discovering and developing novel anti-cancer therapeutics. Their proprietary drug discovery approach, TARTIS, targets tissue-specific vulnerabilities in cancer cells. This innovative approach aims to develop small molecules and shRNAs that selectively kill cells from specific tissues. Their lead product, an orally available NAMPT inhibitor, is currently in Phase 1/2a clinical trials for treating hematological malignancies. The company is dedicated to providing innovative solutions for cancer treatment through targeted therapies. This research and development focuses on precision medicine and personalized healthcare.
- Dec 2017Series B$6M
- Jul 2016Series B$1.9M
- Feb 2012Grant (prize money)$3.6M
- Feb 2011Series A$6.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Buffalo researches in biotechnology
- University at Buffalo, State University of New York15
- Central Institute for Research on Buffaloes2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.